{"id":577,"date":"2022-03-14T10:50:00","date_gmt":"2022-03-14T08:50:00","guid":{"rendered":"https:\/\/www.ipsen.com\/de\/?post_type=press_release&#038;p=577"},"modified":"2023-12-13T12:09:09","modified_gmt":"2023-12-13T10:09:09","slug":"asco-gu-2-jahres-follow-up-der-checkmate-9er-studie-anhaltender-behandlungsvorteil-unter-erstlinientherapie-des-fortgeschrittenen-nierenzellkarzinoms-mit-cabozantinib-plus-nivolumab-vs-sunitinib","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/germany\/press-releases\/asco-gu-2-jahres-follow-up-der-checkmate-9er-studie-anhaltender-behandlungsvorteil-unter-erstlinientherapie-des-fortgeschrittenen-nierenzellkarzinoms-mit-cabozantinib-plus-nivolumab-vs-sunitinib\/","title":{"rendered":"ASCO-GU: 2-Jahres-Follow-up der CheckMate-9ER-Studie: Anhaltender Behandlungsvorteil unter Erstlinientherapie des fortgeschrittenen Nierenzellkarzinoms mit Cabozantinib plus Nivolumab vs. Sunitinib"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"template":"","categories":[29],"tags":[],"class_list":["post-577","press_release","type-press_release","status-publish","has-post-thumbnail","hentry","category-onkologie","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>ASCO-GU: 2-Jahres-Follow-up der CheckMate-9ER-Studie: Anhaltender Behandlungsvorteil unter Erstlinientherapie des fortgeschrittenen Nierenzellkarzinoms mit Cabozantinib plus Nivolumab vs. Sunitinib - Germany<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/germany\/press-releases\/asco-gu-2-jahres-follow-up-der-checkmate-9er-studie-anhaltender-behandlungsvorteil-unter-erstlinientherapie-des-fortgeschrittenen-nierenzellkarzinoms-mit-cabozantinib-plus-nivolumab-vs-sunitinib\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ASCO-GU: 2-Jahres-Follow-up der CheckMate-9ER-Studie: Anhaltender Behandlungsvorteil unter Erstlinientherapie des fortgeschrittenen Nierenzellkarzinoms mit Cabozantinib plus Nivolumab vs. Sunitinib - Germany\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/germany\/press-releases\/asco-gu-2-jahres-follow-up-der-checkmate-9er-studie-anhaltender-behandlungsvorteil-unter-erstlinientherapie-des-fortgeschrittenen-nierenzellkarzinoms-mit-cabozantinib-plus-nivolumab-vs-sunitinib\/\" \/>\n<meta property=\"og:site_name\" content=\"Germany\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-13T10:09:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/06080352\/PR-final.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"856\" \/>\n\t<meta property=\"og:image:height\" content=\"446\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/germany\/press-releases\/asco-gu-2-jahres-follow-up-der-checkmate-9er-studie-anhaltender-behandlungsvorteil-unter-erstlinientherapie-des-fortgeschrittenen-nierenzellkarzinoms-mit-cabozantinib-plus-nivolumab-vs-sunitinib\/\",\"url\":\"https:\/\/www.ipsen.com\/germany\/press-releases\/asco-gu-2-jahres-follow-up-der-checkmate-9er-studie-anhaltender-behandlungsvorteil-unter-erstlinientherapie-des-fortgeschrittenen-nierenzellkarzinoms-mit-cabozantinib-plus-nivolumab-vs-sunitinib\/\",\"name\":\"ASCO-GU: 2-Jahres-Follow-up der CheckMate-9ER-Studie: Anhaltender Behandlungsvorteil unter Erstlinientherapie des fortgeschrittenen Nierenzellkarzinoms mit Cabozantinib plus Nivolumab vs. Sunitinib - Germany\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/germany\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/germany\/press-releases\/asco-gu-2-jahres-follow-up-der-checkmate-9er-studie-anhaltender-behandlungsvorteil-unter-erstlinientherapie-des-fortgeschrittenen-nierenzellkarzinoms-mit-cabozantinib-plus-nivolumab-vs-sunitinib\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/germany\/press-releases\/asco-gu-2-jahres-follow-up-der-checkmate-9er-studie-anhaltender-behandlungsvorteil-unter-erstlinientherapie-des-fortgeschrittenen-nierenzellkarzinoms-mit-cabozantinib-plus-nivolumab-vs-sunitinib\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/06080352\/PR-final.jpg\",\"datePublished\":\"2022-03-14T08:50:00+00:00\",\"dateModified\":\"2023-12-13T10:09:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/germany\/press-releases\/asco-gu-2-jahres-follow-up-der-checkmate-9er-studie-anhaltender-behandlungsvorteil-unter-erstlinientherapie-des-fortgeschrittenen-nierenzellkarzinoms-mit-cabozantinib-plus-nivolumab-vs-sunitinib\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/germany\/press-releases\/asco-gu-2-jahres-follow-up-der-checkmate-9er-studie-anhaltender-behandlungsvorteil-unter-erstlinientherapie-des-fortgeschrittenen-nierenzellkarzinoms-mit-cabozantinib-plus-nivolumab-vs-sunitinib\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/www.ipsen.com\/germany\/press-releases\/asco-gu-2-jahres-follow-up-der-checkmate-9er-studie-anhaltender-behandlungsvorteil-unter-erstlinientherapie-des-fortgeschrittenen-nierenzellkarzinoms-mit-cabozantinib-plus-nivolumab-vs-sunitinib\/#primaryimage\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/06080352\/PR-final.jpg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/06080352\/PR-final.jpg\",\"width\":856,\"height\":446},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/germany\/press-releases\/asco-gu-2-jahres-follow-up-der-checkmate-9er-studie-anhaltender-behandlungsvorteil-unter-erstlinientherapie-des-fortgeschrittenen-nierenzellkarzinoms-mit-cabozantinib-plus-nivolumab-vs-sunitinib\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/germany\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ASCO-GU: 2-Jahres-Follow-up der CheckMate-9ER-Studie: Anhaltender Behandlungsvorteil unter Erstlinientherapie des fortgeschrittenen Nierenzellkarzinoms mit Cabozantinib plus Nivolumab vs. Sunitinib\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/germany\/#website\",\"url\":\"https:\/\/www.ipsen.com\/germany\/\",\"name\":\"Germany\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/germany\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/germany\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/germany\/#organization\",\"name\":\"Germany\",\"url\":\"https:\/\/www.ipsen.com\/germany\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/www.ipsen.com\/germany\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/07165742\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/07165742\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"Germany\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/germany\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ASCO-GU: 2-Jahres-Follow-up der CheckMate-9ER-Studie: Anhaltender Behandlungsvorteil unter Erstlinientherapie des fortgeschrittenen Nierenzellkarzinoms mit Cabozantinib plus Nivolumab vs. Sunitinib - Germany","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/germany\/press-releases\/asco-gu-2-jahres-follow-up-der-checkmate-9er-studie-anhaltender-behandlungsvorteil-unter-erstlinientherapie-des-fortgeschrittenen-nierenzellkarzinoms-mit-cabozantinib-plus-nivolumab-vs-sunitinib\/","og_locale":"de_DE","og_type":"article","og_title":"ASCO-GU: 2-Jahres-Follow-up der CheckMate-9ER-Studie: Anhaltender Behandlungsvorteil unter Erstlinientherapie des fortgeschrittenen Nierenzellkarzinoms mit Cabozantinib plus Nivolumab vs. Sunitinib - Germany","og_url":"https:\/\/www.ipsen.com\/germany\/press-releases\/asco-gu-2-jahres-follow-up-der-checkmate-9er-studie-anhaltender-behandlungsvorteil-unter-erstlinientherapie-des-fortgeschrittenen-nierenzellkarzinoms-mit-cabozantinib-plus-nivolumab-vs-sunitinib\/","og_site_name":"Germany","article_modified_time":"2023-12-13T10:09:09+00:00","og_image":[{"width":856,"height":446,"url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/06080352\/PR-final.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/germany\/press-releases\/asco-gu-2-jahres-follow-up-der-checkmate-9er-studie-anhaltender-behandlungsvorteil-unter-erstlinientherapie-des-fortgeschrittenen-nierenzellkarzinoms-mit-cabozantinib-plus-nivolumab-vs-sunitinib\/","url":"https:\/\/www.ipsen.com\/germany\/press-releases\/asco-gu-2-jahres-follow-up-der-checkmate-9er-studie-anhaltender-behandlungsvorteil-unter-erstlinientherapie-des-fortgeschrittenen-nierenzellkarzinoms-mit-cabozantinib-plus-nivolumab-vs-sunitinib\/","name":"ASCO-GU: 2-Jahres-Follow-up der CheckMate-9ER-Studie: Anhaltender Behandlungsvorteil unter Erstlinientherapie des fortgeschrittenen Nierenzellkarzinoms mit Cabozantinib plus Nivolumab vs. Sunitinib - Germany","isPartOf":{"@id":"https:\/\/www.ipsen.com\/germany\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/germany\/press-releases\/asco-gu-2-jahres-follow-up-der-checkmate-9er-studie-anhaltender-behandlungsvorteil-unter-erstlinientherapie-des-fortgeschrittenen-nierenzellkarzinoms-mit-cabozantinib-plus-nivolumab-vs-sunitinib\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/germany\/press-releases\/asco-gu-2-jahres-follow-up-der-checkmate-9er-studie-anhaltender-behandlungsvorteil-unter-erstlinientherapie-des-fortgeschrittenen-nierenzellkarzinoms-mit-cabozantinib-plus-nivolumab-vs-sunitinib\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/06080352\/PR-final.jpg","datePublished":"2022-03-14T08:50:00+00:00","dateModified":"2023-12-13T10:09:09+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/germany\/press-releases\/asco-gu-2-jahres-follow-up-der-checkmate-9er-studie-anhaltender-behandlungsvorteil-unter-erstlinientherapie-des-fortgeschrittenen-nierenzellkarzinoms-mit-cabozantinib-plus-nivolumab-vs-sunitinib\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/germany\/press-releases\/asco-gu-2-jahres-follow-up-der-checkmate-9er-studie-anhaltender-behandlungsvorteil-unter-erstlinientherapie-des-fortgeschrittenen-nierenzellkarzinoms-mit-cabozantinib-plus-nivolumab-vs-sunitinib\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.ipsen.com\/germany\/press-releases\/asco-gu-2-jahres-follow-up-der-checkmate-9er-studie-anhaltender-behandlungsvorteil-unter-erstlinientherapie-des-fortgeschrittenen-nierenzellkarzinoms-mit-cabozantinib-plus-nivolumab-vs-sunitinib\/#primaryimage","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/06080352\/PR-final.jpg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/06080352\/PR-final.jpg","width":856,"height":446},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/germany\/press-releases\/asco-gu-2-jahres-follow-up-der-checkmate-9er-studie-anhaltender-behandlungsvorteil-unter-erstlinientherapie-des-fortgeschrittenen-nierenzellkarzinoms-mit-cabozantinib-plus-nivolumab-vs-sunitinib\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/germany\/"},{"@type":"ListItem","position":2,"name":"ASCO-GU: 2-Jahres-Follow-up der CheckMate-9ER-Studie: Anhaltender Behandlungsvorteil unter Erstlinientherapie des fortgeschrittenen Nierenzellkarzinoms mit Cabozantinib plus Nivolumab vs. Sunitinib"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/germany\/#website","url":"https:\/\/www.ipsen.com\/germany\/","name":"Germany","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/germany\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/germany\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/germany\/#organization","name":"Germany","url":"https:\/\/www.ipsen.com\/germany\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.ipsen.com\/germany\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/07165742\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/6\/2023\/12\/07165742\/Latest_Ipsen-logo_168x48.svg","caption":"Germany"},"image":{"@id":"https:\/\/www.ipsen.com\/germany\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/germany\/wp-json\/wp\/v2\/press_release\/577","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/germany\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/germany\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/germany\/wp-json\/wp\/v2\/users\/2"}],"version-history":[{"count":3,"href":"https:\/\/www.ipsen.com\/germany\/wp-json\/wp\/v2\/press_release\/577\/revisions"}],"predecessor-version":[{"id":1268,"href":"https:\/\/www.ipsen.com\/germany\/wp-json\/wp\/v2\/press_release\/577\/revisions\/1268"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/germany\/wp-json\/wp\/v2\/media\/538"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/germany\/wp-json\/wp\/v2\/media?parent=577"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/germany\/wp-json\/wp\/v2\/categories?post=577"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/germany\/wp-json\/wp\/v2\/tags?post=577"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}